Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study
Background Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods We measured left ventr...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2019-01, Vol.23 (1), p.85-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 85 |
| container_title | Clinical and experimental nephrology |
| container_volume | 23 |
| creator | Nitta, Kosaku Iimuro, Satoshi Imai, Enyu Matsuo, Seiichi Makino, Hirofumi Akizawa, Tadao Watanabe, Tsuyoshi Ohashi, Yasuo Hishida, Akira |
| description | Background
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined.
Methods
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD.
Results
We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822;
P
= 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173;
P
= 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369;
P
= 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974;
P
= 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999;
P
= 0.0174).
Conclusion
The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients. |
| doi_str_mv | 10.1007/s10157-018-1605-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6344393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2059857359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-6ff2fa925c391562a6bb39676580890f526dd2ab82622233ed26590f87d497ac3</originalsourceid><addsrcrecordid>eNp1kctrFTEYxQdRbK3-AW4k4MbN2DwmycSFUK6PqgVBdB1y87iTdm4yTTKV6co_vbnctj7AVULO7zv5DqdpniP4GkHIjzOCiPIWor5FDNL2-kFziDrCW86FeFjvpMMt4hQdNE9yPocQ9oKKx80BFoIijslh8-ubzxfAKV1iysDFBHzQyapsDRitK-DKhpK8nkeVwLBMNpUUp2GpGJhU8VXN4KcvA9BDisFrcOFNsAswPu9c3gDng_FhU81T3IIyWLD68q79fLICucxmedo8cmrM9tntedT8-PD---q0Pfv68dPq5KzVtBOlZc5hpwSmmghEGVZsvSaCcUb7Ggo6ipkxWK17zDDGhFiDGa3vPTed4EqTo-bt3nea11tr9C6WGuWU_FalRUbl5d9K8IPcxCvJSNcRQarBq1uDFC9nm4vc-qztOKpg45wlhgx1kNftKvryH_Q8zinUeJWioqecUFEptKd0ijkn6-6XQVDu-pX7fmXtV-76ldd15sWfKe4n7gqtAN4DuUphY9Pvr__vegOf6LK8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2059857359</pqid></control><display><type>article</type><title>Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Nitta, Kosaku ; Iimuro, Satoshi ; Imai, Enyu ; Matsuo, Seiichi ; Makino, Hirofumi ; Akizawa, Tadao ; Watanabe, Tsuyoshi ; Ohashi, Yasuo ; Hishida, Akira</creator><creatorcontrib>Nitta, Kosaku ; Iimuro, Satoshi ; Imai, Enyu ; Matsuo, Seiichi ; Makino, Hirofumi ; Akizawa, Tadao ; Watanabe, Tsuyoshi ; Ohashi, Yasuo ; Hishida, Akira</creatorcontrib><description>Background
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined.
Methods
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD.
Results
We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822;
P
= 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173;
P
= 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369;
P
= 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974;
P
= 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999;
P
= 0.0174).
Conclusion
The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-018-1605-z</identifier><identifier>PMID: 29951723</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Blood pressure ; Body mass index ; Cardiovascular diseases ; Cholesterol ; Diabetes mellitus ; Dialysis ; Health risk assessment ; Heart ; Hypertrophy ; Kidney diseases ; Kidneys ; Medicine ; Medicine & Public Health ; Nephrology ; Original ; Original Article ; Renal function ; Risk factors ; Urology ; Ventricle</subject><ispartof>Clinical and experimental nephrology, 2019-01, Vol.23 (1), p.85-98</ispartof><rights>The Author(s) 2018</rights><rights>Clinical and Experimental Nephrology is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-6ff2fa925c391562a6bb39676580890f526dd2ab82622233ed26590f87d497ac3</citedby><cites>FETCH-LOGICAL-c549t-6ff2fa925c391562a6bb39676580890f526dd2ab82622233ed26590f87d497ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-018-1605-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-018-1605-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29951723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nitta, Kosaku</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><creatorcontrib>Imai, Enyu</creatorcontrib><creatorcontrib>Matsuo, Seiichi</creatorcontrib><creatorcontrib>Makino, Hirofumi</creatorcontrib><creatorcontrib>Akizawa, Tadao</creatorcontrib><creatorcontrib>Watanabe, Tsuyoshi</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Hishida, Akira</creatorcontrib><title>Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined.
Methods
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD.
Results
We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822;
P
= 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173;
P
= 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369;
P
= 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974;
P
= 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999;
P
= 0.0174).
Conclusion
The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.</description><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Diabetes mellitus</subject><subject>Dialysis</subject><subject>Health risk assessment</subject><subject>Heart</subject><subject>Hypertrophy</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Original</subject><subject>Original Article</subject><subject>Renal function</subject><subject>Risk factors</subject><subject>Urology</subject><subject>Ventricle</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kctrFTEYxQdRbK3-AW4k4MbN2DwmycSFUK6PqgVBdB1y87iTdm4yTTKV6co_vbnctj7AVULO7zv5DqdpniP4GkHIjzOCiPIWor5FDNL2-kFziDrCW86FeFjvpMMt4hQdNE9yPocQ9oKKx80BFoIijslh8-ubzxfAKV1iysDFBHzQyapsDRitK-DKhpK8nkeVwLBMNpUUp2GpGJhU8VXN4KcvA9BDisFrcOFNsAswPu9c3gDng_FhU81T3IIyWLD68q79fLICucxmedo8cmrM9tntedT8-PD---q0Pfv68dPq5KzVtBOlZc5hpwSmmghEGVZsvSaCcUb7Ggo6ipkxWK17zDDGhFiDGa3vPTed4EqTo-bt3nea11tr9C6WGuWU_FalRUbl5d9K8IPcxCvJSNcRQarBq1uDFC9nm4vc-qztOKpg45wlhgx1kNftKvryH_Q8zinUeJWioqecUFEptKd0ijkn6-6XQVDu-pX7fmXtV-76ldd15sWfKe4n7gqtAN4DuUphY9Pvr__vegOf6LK8</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Nitta, Kosaku</creator><creator>Iimuro, Satoshi</creator><creator>Imai, Enyu</creator><creator>Matsuo, Seiichi</creator><creator>Makino, Hirofumi</creator><creator>Akizawa, Tadao</creator><creator>Watanabe, Tsuyoshi</creator><creator>Ohashi, Yasuo</creator><creator>Hishida, Akira</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study</title><author>Nitta, Kosaku ; Iimuro, Satoshi ; Imai, Enyu ; Matsuo, Seiichi ; Makino, Hirofumi ; Akizawa, Tadao ; Watanabe, Tsuyoshi ; Ohashi, Yasuo ; Hishida, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-6ff2fa925c391562a6bb39676580890f526dd2ab82622233ed26590f87d497ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Diabetes mellitus</topic><topic>Dialysis</topic><topic>Health risk assessment</topic><topic>Heart</topic><topic>Hypertrophy</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Original</topic><topic>Original Article</topic><topic>Renal function</topic><topic>Risk factors</topic><topic>Urology</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nitta, Kosaku</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><creatorcontrib>Imai, Enyu</creatorcontrib><creatorcontrib>Matsuo, Seiichi</creatorcontrib><creatorcontrib>Makino, Hirofumi</creatorcontrib><creatorcontrib>Akizawa, Tadao</creatorcontrib><creatorcontrib>Watanabe, Tsuyoshi</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Hishida, Akira</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nitta, Kosaku</au><au>Iimuro, Satoshi</au><au>Imai, Enyu</au><au>Matsuo, Seiichi</au><au>Makino, Hirofumi</au><au>Akizawa, Tadao</au><au>Watanabe, Tsuyoshi</au><au>Ohashi, Yasuo</au><au>Hishida, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>23</volume><issue>1</issue><spage>85</spage><epage>98</epage><pages>85-98</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><abstract>Background
Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined.
Methods
We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD.
Results
We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822;
P
= 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173;
P
= 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369;
P
= 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974;
P
= 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999;
P
= 0.0174).
Conclusion
The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>29951723</pmid><doi>10.1007/s10157-018-1605-z</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2019-01, Vol.23 (1), p.85-98 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6344393 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Blood pressure Body mass index Cardiovascular diseases Cholesterol Diabetes mellitus Dialysis Health risk assessment Heart Hypertrophy Kidney diseases Kidneys Medicine Medicine & Public Health Nephrology Original Original Article Renal function Risk factors Urology Ventricle |
| title | Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T10%3A07%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20increased%20left%20ventricular%20hypertrophy%20in%20patients%20with%20chronic%20kidney%20disease:%20findings%20from%20the%20CKD-JAC%20study&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Nitta,%20Kosaku&rft.date=2019-01-01&rft.volume=23&rft.issue=1&rft.spage=85&rft.epage=98&rft.pages=85-98&rft.issn=1342-1751&rft.eissn=1437-7799&rft_id=info:doi/10.1007/s10157-018-1605-z&rft_dat=%3Cproquest_pubme%3E2059857359%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2059857359&rft_id=info:pmid/29951723&rfr_iscdi=true |